Physician profile
Carolynn S Francavilla Brown
NPI 1568753739
$173,952.57
in general payments reported to CMS, 2019-2025
15 companies · $94K in 2025
The $94K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.80 · 2022: $478 · 2023: $1,141 · 2024: $78K · 2025: $94K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $149K · Travel and Lodging: $13K · Consulting Fee: $7,165 · Food and Beverage: $4,559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $148,925.00 |
| Travel and Lodging | $12,808.60 |
| Consulting Fee | $7,165.00 |
| Food and Beverage | $4,559.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $167,327.92 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $4,090.98 | 2022-2025 | Wegovy, Saxenda |
| Eli Lilly and Company | $1,575.00 | 2025 | Mounjaro |
| Abbvie INC. | $207.52 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $154.52 | 2025 | |
| Lucid Diagnostics INC. | $123.80 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $117.48 | 2023-2024 | Imcivree, Imcivree |
| Chiesi USA, INC. | $112.11 | 2025 | Myalept |
| Pfizer INC. | $75.81 | 2023-2025 | |
| Corcept Therapeutics | $46.12 | 2025 | Korlym |
| Astellas Pharma US INC | $41.58 | 2023-2025 | Veozah |
| Abbott Laboratories | $22.61 | 2025 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $19.23 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals Lp | $19.14 | 2024 | |
| Exeltis, USA INC. | $18.75 | 2025 | Slynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carolynn Francavilla Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.